Best Agrolife Ltd

Key Agenda Items

• Approve Director's Report, Corporate Governance Report, MD&A, CSR Report, and Secretarial Audit for FY ended 31 Mar 2026.
• Appoint practicing company secretary as Scrutinizer for the 35th AGM to scrutinize voting.
• Consider and approve Notice for the 35th AGM and fix date/time.

Meeting Details

• Date: August 70, 2026; time not specified.
• Type/Mode: group, physical road show.
• Event/Organizer: No Deal Road Show.
• Venue: ITC Maratha, Mumbai.
• Purpose: investor interaction with company officials.
• Key participants: company officials (roles not specified).

Meeting Details

• Date of posting: July 31, 2026.
• Meeting type: earnings conference call (audio recording).
• Mode: virtual/audio recording on the company's website.

Participants

• Key company roles: Compliance Officer (signatory).
• Management participants not explicitly named.

Purpose

• Availability of earnings conference call recording for the quarter ended June 30, 2026.

Additional Notes

• Recording uploaded on the company's website; no links included.

Q1 FY27 performance

• Revenue from operations at ₹396 crore, up 4% YoY from ₹381 crore.
• Gross margin improved to 37% from 29% in Q1 FY26.
• EBITDA margin rose to 20% from 12%, driven by mix, price increases, and cost control.
• PAT at ₹41 crore, up 104% YoY.
• PAT margin expanded to 10% from 5% in Q1 FY26.
• Sequentially profitable versus Q4 FY26, with revenue, EBITDA, and PAT turning positive.
• Key products Best Man, Fetagen, Warden Extra, Ronfen gaining acceptance; Fluzam and Cubax Power Extra expanding.
• Outlook remains positive with improving monsoon activity and momentum in peak Kharif season.
• Registrations for several 9(3) and 9(4) products disclosed.

Deviation and fund utilisation

• Purpose: Deviation/Variation statement for funds raised via warrants.
• Mode: Preferential issue of convertible warrants.
• Date raised: 27-12-2024.
• Amount raised: ₹150 crore.
• Monitoring agency: CRISIL Ratings Limited.
• Deviation status: No deviation or variation in use of funds.
• Audit Committee: Approved this statement on 30 July 2026.
• Utilisation status: No utilisation in current quarter; full utilisation completed by June 2025.

Financial performance

• Revenue from operations: 396 crore, up 4% YoY from 381 crore.
• Gross profit: 146 crore, up 32% YoY; gross margin 37%.
• PAT: 41 crore, up 104% YoY; PAT margin 10%.
• EBITDA: 78 crore, up 70% YoY; EBITDA margin 20%.
• Operating expenses including finance costs and depreciation: 92.97 crore, up 4%.
• Inventory: 76.64 crore, down 60% YoY.
• New products Fluzam and Cubax Power Extra gaining adoption.

Operational commentary

• Monsoon delays impacted seed treatment demand; demand improving with better monsoon.

Outlook & management commentary

• MD cites margin expansion due to product mix, price increases, and cost management.
• Sees momentum in peak Kharif season; optimistic about FY27 growth.